Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5

Journal of Bone and Mineral Research

Volumn 26, Issue 8, 2011, Pages 1721-1728

  Frost, Morten ^a   Andersen, Tom ^a   Gossiel, Fatma ^b   Hansen, Stinus ^a   Bollerslev, Jens ^c,d   Van Hul, Wim ^e   Eastell, Richard ^b   Kassem, Moustapha ^a,f   Brixen, Kim ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

bone turnover markers; DKK1; DXA; high bone mass; HR pQCT; Lrp5; sclerostin; serum serotonin

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; SCLEROSTIN; SEROTONIN;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE MATURATION; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOREARM; GENE; HIP; HUMAN; LRP5 GENE; LUMBAR SPINE; MALE; PHENOTYPE; SEROTONIN BLOOD LEVEL; THICKNESS; TIBIA; TRABECULAR BONE;

ABSORPTIOMETRY, PHOTON; ADULT; AGING; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CASE-CONTROL STUDIES; FEMALE; GENETIC MARKERS; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MALE; MIDDLE AGED; MUTATION; ORGAN SIZE; PHENOTYPE; SEROTONIN; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 79960640529     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.376     Document Type: Article

References (35)

1. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107: 513-523. (Pubitemid 33152786)
2. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002; 346: 1513-1521. (Pubitemid 34755690)
3. Van WL, Cleiren E, Gram J, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003; 72: 763-771. (Pubitemid 36255977)
4. Balemans W, Piters E, Cleiren E, et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int. 2008; 82: 445-453.
5. Ai M, Holmen SL, Van HW, Williams BO, Warman ML,. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol. 2005; 25: 4946-4955. (Pubitemid 40781096)
6. Balemans W, Devogelaer JP, Cleiren E, Piters E, Caussin E, Van HW,. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. J Bone Miner Res. 2007; 22: 708-716. (Pubitemid 351339099)
7. Bollerslev J, Marks SC Jr, Pockwinse S, et al. Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone. 1993; 14: 865-869. (Pubitemid 24012696)
8. Henriksen K, Gram J, Hoegh-Andersen P, et al. Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo. Am J Pathol. 2005; 167: 1341-1348. (Pubitemid 41541420)
9. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135: 825-837.
10. Frost M, Andersen TE, Yadav V, Brixen K, Karsenty G, Kassem M,. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J Bone Miner Res. 2010; 25: 673-675.
11. Bollerslev J, Andersen PE Jr., Radiological, biochemical and hereditary evidence of two types of autosomal dominant osteopetrosis. Bone. 1988; 9: 7-13.
12. Bollerslev J, Nielsen HK, Larsen HF, Mosekilde L,. Biochemical evidence of disturbed bone metabolism and calcium homeostasis in two types of autosomal dominant osteopetrosis. Acta Med Scand. 1988; 224: 479-483. (Pubitemid 19052197)
13. Bollerslev J, Mosekilde L, Nielsen HK, Mosekilde L,. Biomechanical competence of iliac crest trabecular bone in autosomal dominant osteopetrosis type I. Bone. 1989; 10: 159-164. (Pubitemid 19249341)
14. Bollerslev J, Thomas S, Grodum E, Brixen K, Djoseland O,. Collagen metabolism in two types of autosomal dominant osteopetrosis during stimulation with thyroid hormones. Eur J Endocrinol. 1995; 133: 557-563.
15. Bollerslev J, Ueland T, Grodum E, Haug E, Brixen K, Djoseland O,. Biochemical markers of bone metabolism in benign human osteopetrosis: a study of two types at baseline and during stimulation with triiodothyronine. Eur J Endocrinol. 1998; 139: 29-35. (Pubitemid 28351232)
16. Brockstedt H, Bollerslev J, Melsen F, Mosekilde L,. Cortical bone remodeling in autosomal dominant osteopetrosis: a study of two different phenotypes. Bone. 1996; 18: 67-72. (Pubitemid 26047535)
17. Bollerslev J, Steiniche T, Melsen F, Mosekilde L,. Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types. Bone. 1989; 10: 19-24. (Pubitemid 19134740)
18. Bollerslev J, Andersen PE Jr., Fracture patterns in two types of autosomal-dominant osteopetrosis. Acta Orthop Scand. 1989; 60: 110-112. (Pubitemid 19090574)
19. Muller R, Hildebrand T, Hauselmann HJ, Ruegsegger P,. In vivo reproducibility of three-dimensional structural properties of noninvasive bone biopsies using 3D-pQCT. J Bone Miner Res. 1996; 11: 1745-1750. (Pubitemid 26367685)
20. Richards JB, Kavvoura FK, Rivadeneira F, et al. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med. 2009; 151: 528-537.
21. Rickels MR, Zhang X, Mumm S, Whyte MP,. Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation. J Bone Miner Res. 2005; 20: 878-885. (Pubitemid 40571645)
22. Grodum E, Gram J, Brixen K, Bollerslev J,. Autosomal dominant osteopetrosis: bone mineral measurements of the entire skeleton of adults in two different subtypes. Bone. 1995; 16: 431-434.
23. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002; 70: 11-19. (Pubitemid 34031693)
24. Riggs BL, Melton LJ, Robb RA, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res. 2008; 23: 205-214. (Pubitemid 351160034)
25. Babij P, Zhao W, Small C, Kharode Y, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res. 2003; 18: 960-974. (Pubitemid 37294932)
26. Akhter MP, Wells DJ, Short SJ, et al. Bone biomechanical properties in LRP5 mutant mice. Bone. 2004; 35: 162-169. (Pubitemid 38789159)
27. Sawakami K, Robling AG, Ai M, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006; 281: 23698-23711. (Pubitemid 44274145)
28. Kiel DP, Ferrari SL, Cupples LA, et al. Genetic variation at the low-density lipoprotein receptor-related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity with bone mineral density in men. Bone. 2007; 40: 587-596. (Pubitemid 46187219)
29. Brixen K, Beckers S, Peeters A, et al. Polymorphisms in the Low-Density Lipoprotein Receptor-Related Protein 5 (LRP5) Gene Are Associated with Peak Bone Mass in Non-sedentary Men: Results from the Odense Androgen Study. Calcif Tissue Int. 2007; 81: 421-429.
30. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280: 19883-19887. (Pubitemid 41379516)
31. Gaudio A, Pennisi P, Bratengeier C, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95: 2248-2253.
32. Qiu W, Andersen TE, Bollerslev J, Mandrup S, Abdallah BM, Kassem M,. Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells 11. J Bone Miner Res. 2007; 22: 1720-1731. (Pubitemid 351235138)
33. Yadav VK, Balaji S, Suresh PS, et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010; 16: 308-312.
34. Mödder UI, Achenbach SJ, Amin S, Riggs BL, Melton LJ, Khosla S,. Relation of Serum Serotonin Levels to Bone Density and Structural Parameters in Women. J Bone Miner Res. 2009; 2010 Feb; 25: 415-422.
35. Sekhon K, Kazakia GJ, Burghardt AJ, Hermannsson B, Majumdar S,. Accuracy of volumetric bone mineral density measurement in high-resolution peripheral quantitative computed tomography. Bone. 2009; 45: 473-479.